Literature DB >> 31481573

Multimodality Imaging of Prostate Cancer.

Soleen Ghafoor1, Irene A Burger2, Alberto H Vargas3.   

Abstract

Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors. In recent years, imaging has gained increasing importance in the detection, staging, posttreatment assessment, and detection of recurrence of prostate cancer. Several imaging modalities including conventional and functional methods are used in different clinical scenarios with their very own advantages and limitations. This continuing medical education article provides an overview of available imaging modalities currently in use for prostate cancer followed by a more specific section on the value of these different imaging modalities in distinct clinical scenarios, ranging from initial diagnosis to advanced, metastatic castration-resistant prostate cancer. In addition to established imaging indications, we will highlight some potential future applications of contemporary imaging modalities in prostate cancer.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET/MRI; PSMA; fluciclovine; multiparametric MRI; theranostics; whole-body MRI

Mesh:

Substances:

Year:  2019        PMID: 31481573      PMCID: PMC6785785          DOI: 10.2967/jnumed.119.228320

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  77 in total

Review 1.  Intratumor heterogeneity in prostate cancer.

Authors:  Shalini S Yadav; Jennifer A Stockert; Victoria Hackert; Kamlesh K Yadav; Ashutosh K Tewari
Journal:  Urol Oncol       Date:  2018-06-07       Impact factor: 3.498

2.  PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.

Authors:  Bernhard Grubmüller; Pascal Baltzer; Sabrina Hartenbach; David D'Andrea; Thomas H Helbich; Alexander R Haug; Gregor M Goldner; Wolfgang Wadsak; Sarah Pfaff; Markus Mitterhauser; Theresa Balber; Neydher Berroteran-Infante; Marko Grahovac; John Babich; Christian Seitz; Gero Kramer; Martin Susani; Peter Mazal; Lukas Kenner; Shahrokh F Shariat; Marcus Hacker; Markus Hartenbach
Journal:  Clin Cancer Res       Date:  2018-08-23       Impact factor: 12.531

3.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

4.  Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.

Authors:  Helle D Zacho; Julie B Nielsen; Ali Afshar-Oromieh; Uwe Haberkorn; Nandita deSouza; Katja De Paepe; Katja Dettmann; Niels C Langkilde; Christian Haarmark; Rune V Fisker; Dennis T Arp; Jesper Carl; Jørgen B Jensen; Lars J Petersen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

Review 5.  Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

Authors:  Laura Evangelista; Andrea Guttilla; Fabio Zattoni; Pier Carlo Muzzio; Filiberto Zattoni
Journal:  Eur Urol       Date:  2012-09-25       Impact factor: 20.096

6.  A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.

Authors:  Michael S Hofman; Declan G Murphy; Scott G Williams; Tatenda Nzenza; Alan Herschtal; Richard De Abreu Lourenco; Dale L Bailey; Ray Budd; Rodney J Hicks; Roslyn J Francis; Nathan Lawrentschuk
Journal:  BJU Int       Date:  2018-06-03       Impact factor: 5.588

Review 7.  Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy.

Authors:  L M Wu; J-R Xu; H Y Gu; J Hua; J Zhu; J Chen; W Zhang; J Hu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-01-11       Impact factor: 4.126

8.  Detection Rate of 18F-Choline PET/CT and 68Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes.

Authors:  Cordula A Jilg; Vanessa Drendel; H Christian Rischke; Teresa I Beck; Kathrin Reichel; Malte Krönig; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Philipp T Meyer; Werner Vach
Journal:  J Nucl Med       Date:  2019-01-25       Impact factor: 10.057

9.  What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.

Authors:  Samuel Borofsky; Arvin K George; Sonia Gaur; Marcelino Bernardo; Matthew D Greer; Francesca V Mertan; Myles Taffel; Vanesa Moreno; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2017-10-20       Impact factor: 11.105

Review 10.  Rationale for Modernising Imaging in Advanced Prostate Cancer.

Authors:  Anwar R Padhani; Frederic E Lecouvet; Nina Tunariu; Dow-Mu Koh; Frederik De Keyzer; David J Collins; Evis Sala; Stefano Fanti; H Alberto Vargas; Giuseppe Petralia; Heinz Peter Schlemmer; Bertrand Tombal; Johann de Bono
Journal:  Eur Urol Focus       Date:  2016-07-15
View more
  13 in total

1.  Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.

Authors:  Pierpaolo Alongi; Alessandro Stefano; Albert Comelli; Riccardo Laudicella; Salvatore Scalisi; Giuseppe Arnone; Stefano Barone; Massimiliano Spada; Pierpaolo Purpura; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giorgio Russo
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

Review 2.  The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1.

Authors:  Hsiaoju S Lee; Sally W Schwarz; Erin K Schubert; Delphine L Chen; Robert K Doot; Mehran Makvandi; Lilie L Lin; Elizabeth S McDonald; David A Mankoff; Robert H Mach
Journal:  Radiol Imaging Cancer       Date:  2022-01

3.  Magnetic Iron Oxide Nanoparticles for Biomedical Applications.

Authors:  Kaiyi Jiang; Linlin Zhang; Gang Bao
Journal:  Curr Opin Biomed Eng       Date:  2021-08-17

Review 4.  Recent Advancements in CT and MR Imaging of Prostate Cancer.

Authors:  Asha Daryanani; Baris Turkbey
Journal:  Semin Nucl Med       Date:  2021-12-18       Impact factor: 4.802

5.  Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.

Authors:  Ricarda Hinzpeter; Livia Baumann; Roman Guggenberger; Martin Huellner; Hatem Alkadhi; Bettina Baessler
Journal:  Eur Radiol       Date:  2021-09-24       Impact factor: 7.034

6.  [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL.

Authors:  Elisa Perry; Arpit Talwar; Kim Taubman; Michael Ng; Lih-Ming Wong; Russell Booth; Tom R Sutherland
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-05       Impact factor: 9.236

Review 7.  A review of the application of machine learning in molecular imaging.

Authors:  Lin Yin; Zhen Cao; Kun Wang; Jie Tian; Xing Yang; Jianhua Zhang
Journal:  Ann Transl Med       Date:  2021-05

Review 8.  [Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].

Authors:  Ergela Hasa; Thomas Langbein; Matthias Eiber; Karina Knorr
Journal:  Radiologe       Date:  2021-08-05       Impact factor: 0.635

Review 9.  Whole-body MRI: detecting bone metastases from prostate cancer.

Authors:  Katsuyuki Nakanishi; Junichiro Tanaka; Yasuhiro Nakaya; Noboru Maeda; Atsuhiko Sakamoto; Akiko Nakayama; Hiroki Satomura; Mio Sakai; Koji Konishi; Yoshiyuki Yamamoto; Akira Nagahara; Kazuo Nishimura; Satoshi Takenaka; Noriyuki Tomiyama
Journal:  Jpn J Radiol       Date:  2021-10-25       Impact factor: 2.374

10.  The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis.

Authors:  Rang Wang; Guohua Shen; Mingxing Huang; Rong Tian
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.